BRPI0923480A2 - formas polimorficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabricacao das mesmas - Google Patents

formas polimorficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabricacao das mesmas

Info

Publication number
BRPI0923480A2
BRPI0923480A2 BRPI0923480A BRPI0923480A BRPI0923480A2 BR PI0923480 A2 BRPI0923480 A2 BR PI0923480A2 BR PI0923480 A BRPI0923480 A BR PI0923480A BR PI0923480 A BRPI0923480 A BR PI0923480A BR PI0923480 A2 BRPI0923480 A2 BR PI0923480A2
Authority
BR
Brazil
Prior art keywords
pyridazin
morpholin
pyrazol
pyrimidin
ethoxy
Prior art date
Application number
BRPI0923480A
Other languages
English (en)
Inventor
Axel Becker
Christoph Saal
Clemens Kuehn
Cristina Donini
Dieter Dorsch
Eva Kriegbaum
Frank Stieber
Oliver Schadt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41609799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923480(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0923480A2 publication Critical patent/BRPI0923480A2/pt
Publication of BRPI0923480B1 publication Critical patent/BRPI0923480B1/pt
Publication of BRPI0923480B8 publication Critical patent/BRPI0923480B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0923480A 2008-12-22 2009-11-24 formas polimórficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etóxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona, seus processos de fabricação, composição farmacêutica, medicamento, e kit BRPI0923480B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08022253.2 2008-12-22
EP08022253 2008-12-22
PCT/EP2009/008358 WO2010072295A1 (en) 2008-12-22 2009-11-24 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof

Publications (3)

Publication Number Publication Date
BRPI0923480A2 true BRPI0923480A2 (pt) 2016-08-09
BRPI0923480B1 BRPI0923480B1 (pt) 2020-10-13
BRPI0923480B8 BRPI0923480B8 (pt) 2021-05-25

Family

ID=41609799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923480A BRPI0923480B8 (pt) 2008-12-22 2009-11-24 formas polimórficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etóxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona, seus processos de fabricação, composição farmacêutica, medicamento, e kit

Country Status (32)

Country Link
US (1) US8586599B2 (pt)
EP (1) EP2361250B1 (pt)
JP (2) JP5690741B2 (pt)
KR (1) KR101663335B1 (pt)
CN (1) CN102264729B (pt)
AR (1) AR074686A1 (pt)
AU (1) AU2009331990B2 (pt)
BR (1) BRPI0923480B8 (pt)
CA (1) CA2748218C (pt)
CL (1) CL2011001278A1 (pt)
CO (1) CO6331435A2 (pt)
CY (1) CY1114659T1 (pt)
DK (1) DK2361250T3 (pt)
EA (1) EA019320B1 (pt)
EC (1) ECSP11011219A (pt)
ES (1) ES2434247T3 (pt)
HK (1) HK1164837A1 (pt)
HR (1) HRP20130993T1 (pt)
IL (1) IL213647A (pt)
MX (1) MX2011006682A (pt)
MY (1) MY160526A (pt)
NZ (1) NZ594172A (pt)
PE (1) PE20120016A1 (pt)
PL (1) PL2361250T3 (pt)
PT (1) PT2361250E (pt)
SG (1) SG172128A1 (pt)
SI (1) SI2361250T1 (pt)
SM (1) SMT201300133B (pt)
TW (1) TWI448463B (pt)
UA (1) UA103646C2 (pt)
WO (1) WO2010072295A1 (pt)
ZA (1) ZA201105394B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
EP3697776B1 (en) 2017-10-17 2023-04-19 Palau Pharma, S.L.U. Synthesis of 4-aminopyrimidine compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
US20040259863A1 (en) 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
BR0317525A (pt) 2002-12-20 2005-11-16 Pharmacia Corp Compostos pirazol acìclico, composição terapêutica e farmacêutica, kit, bem como respectivos usos
US7250417B2 (en) 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
WO2006015263A2 (en) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
EP1963329B1 (en) 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
MX2008008277A (es) 2005-12-21 2009-03-04 Janssen Pharmaceutica Nv Triazolopiridazinas como moduladores de tirosina cinasa.
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PE20091079A1 (es) 2007-10-16 2009-08-24 Novartis Ag Compuestos heterociclicos como moduladores npy y2
ATE523508T1 (de) 2007-10-25 2011-09-15 Astrazeneca Ab Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
RU2010121763A (ru) 2007-10-31 2011-12-10 Ниссан Кемикал Индастриз, Лтд. (Jp) Производные пиридазинона и ингибиторы р2х7 рецептора
AR069545A1 (es) 2007-11-16 2010-02-03 Boehringer Ingelheim Pharma Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
AR069869A1 (es) 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
WO2009080364A1 (en) 2007-12-21 2009-07-02 Synthon B.V. Raloxifene composition
CN101952286A (zh) 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
JP5498396B2 (ja) 2007-12-21 2014-05-21 パラウ・フアルマ・ソシエダツド・アノニマ ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
KR101610415B1 (ko) 2007-12-21 2016-04-07 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CN101538245B (zh) 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
JP5390610B2 (ja) 2008-07-25 2014-01-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
BRPI1013159A2 (pt) 2009-03-30 2015-09-15 Sumitomo Chemical Co Uso de composto de piridazinona para controle de peste artrópode
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
CO6331435A2 (es) 2011-10-20
CY1114659T1 (el) 2016-10-05
BRPI0923480B1 (pt) 2020-10-13
PL2361250T3 (pl) 2014-01-31
SI2361250T1 (sl) 2013-12-31
CL2011001278A1 (es) 2011-09-30
CA2748218A1 (en) 2010-07-01
TWI448463B (zh) 2014-08-11
PE20120016A1 (es) 2012-01-24
HK1164837A1 (en) 2012-09-28
KR101663335B1 (ko) 2016-10-06
HRP20130993T1 (hr) 2013-11-22
AU2009331990B2 (en) 2016-04-14
WO2010072295A1 (en) 2010-07-01
EP2361250B1 (en) 2013-08-07
SMT201300133B (it) 2014-03-07
JP2012513417A (ja) 2012-06-14
IL213647A (en) 2013-11-28
TW201028409A (en) 2010-08-01
US20110257180A1 (en) 2011-10-20
US8586599B2 (en) 2013-11-19
AR074686A1 (es) 2011-02-02
MX2011006682A (es) 2011-07-13
JP5860125B2 (ja) 2016-02-16
EP2361250A1 (en) 2011-08-31
UA103646C2 (ru) 2013-11-11
DK2361250T3 (da) 2013-11-04
KR20110089462A (ko) 2011-08-08
PT2361250E (pt) 2013-11-11
NZ594172A (en) 2013-04-26
MY160526A (en) 2017-03-15
CA2748218C (en) 2017-08-29
CN102264729B (zh) 2014-03-05
ZA201105394B (en) 2012-03-28
BRPI0923480B8 (pt) 2021-05-25
AU2009331990A1 (en) 2011-08-11
EA019320B1 (ru) 2014-02-28
ECSP11011219A (es) 2011-12-30
CN102264729A (zh) 2011-11-30
JP5690741B2 (ja) 2015-03-25
ES2434247T3 (es) 2013-12-16
IL213647A0 (en) 2011-07-31
SG172128A1 (en) 2011-07-28
JP2015028093A (ja) 2015-02-12
EA201100973A1 (ru) 2012-01-30

Similar Documents

Publication Publication Date Title
CO7071131A2 (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
BRPI1012108A2 (pt) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrila como inibidores de jak
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0921821A2 (pt) disperções de poliuretano reticuláveis
BRPI0808105A2 (pt) Revestimento hidrófilo
BRPI0920450A2 (pt) Pirrolobenzodiazepinas
HK1154383A1 (en) Pyrazolo quinazolines
BRPI1012087A2 (pt) seleção de mídia compartilhada com avatar integrado
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase
BR112013013898A2 (pt) compostos de pirimidinona para o uso no tratamento de doenças ou condições mediadas por lp-pla2
BRPI0811495A2 (pt) Aplicador de acabamento de piso
BRPI0922013A2 (pt) gavetas de refrigerador com acabamento
EP2375954A4 (en) FUSSBODENPOLITURAPPLIKATOR
DK2188291T3 (da) Fusionerede bicykliske pyrimidiner
BRPI0907954A2 (pt) Tratamento de hipertensão com 25-hidroxivitamina d3
BRPI0814512A2 (pt) Aplicador de acabamento de piso
GB0816741D0 (en) Array of aircraft seats - interlocking herringbone
EP2274444A4 (en) METHOD FOR DIAGNOSING A CHRONIC EXHAUSTION OF ALLOGENIC HEART TRANSPLANTS
BRPI0816718A2 (pt) Fabricação contínua de poliuretano/poliureias
BRPI0923480A2 (pt) formas polimorficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabricacao das mesmas
BRPI1009006A2 (pt) formas cristalinas de 6-(1h-imidazol-1-il)-2-fenil-quinazolina.
BRPI0919511A2 (pt) métodos de redução de células t auxiliares de células b para o tratamento de doenças autoimunes
DE112008003581A5 (de) Fertigbauelement
ES2389424B1 (es) Procedimiento para la visualizacion de superficies en el cuerpo humano.
DK2324111T3 (da) Yderzone-tumorceller samt fremgangsmåde til fremstilling deraf samt anvendelse deraf

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF